LAVAL, QC / ACCESSWIRE / May 17, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals, Ltd., today announced that they will be presenting data from its Phase 2 trial evaluating Amiselimod as treatment for active ulcerative colitis (UC).

拉瓦尔，QC/ACCESSWIRE/2024年5月17日/Bausch Health Companys Inc.（纽约证券交易所：BHC）（TSX：BHC）及其胃肠学（GI）业务Salix Pharmaceuticals，Ltd.今天宣布，他们将提供其评估阿米司莫德治疗活动性溃疡性结肠炎（UC）的2期试验数据。

The data will be presented at Digestive Disease Week (DDW) 2024 during the IMIBD Late Breakers and Innovations in IBD session on Sunday, May 19, 2024, in Washington, D.C..

这些数据将于2024年5月19日（星期日）在华盛顿举行的IBD晚期破坏者和创新会议上于2024年消化疾病周（DDW）上公布。。

'We are pleased to present late-breaking data on Amiselimod, our investigational, oral, sphingosine 1-phosphate (S1P) receptor modulator as a potential treatment for the induction of remission in UC,' said Tage Ramakrishna, M.D., Chief Medical Officer and President of Research & Development, Bausch Health.

Bausch Health首席医学官兼研发总裁Tage Ramakrishna医学博士说：“我们很高兴提供阿米塞利莫德（Amiselimod）的最新数据，阿米塞利莫德是我们的研究性口服1-磷酸鞘氨醇（S1P）受体调节剂，可作为诱导UC缓解的潜在治疗方法。”。

'The abstract underscores our steadfast commitment to developing new and innovative therapies for patients with UC.'.

“摘要强调了我们对为UC患者开发新的创新疗法的坚定承诺。”。

The research to be featured at DDW 2024 and available via the meeting's online platform is as follows:

该研究将在2024年DDW大会上展出，并通过会议的在线平台提供，如下所示：

Hanauer, Stephen B. et al. 'Amiselimod for the treatment of active ulcerative colitis: a randomized, double-blind, placebo-controlled trial' Abstract #4094796

Hanauer，Stephen B.等人，“阿米西莫德治疗活动性溃疡性结肠炎：一项随机，双盲，安慰剂对照试验”摘要#4094796

The Phase 2 clinical trial was a 12-week, double-blind, placebo-controlled, randomized, dose ranging study to evaluate the efficacy and safety of Amiselimod in 320 patients with mildly-to- moderately active UC. Bausch Health announced positive topline results from this study in December 2023.

2期临床试验是一项为期12周，双盲，安慰剂对照，随机，剂量范围的研究，旨在评估阿米司莫德对320例轻度至中度活动性UC患者的疗效和安全性。Bausch Health于2023年12月宣布了这项研究的积极结果。

About Amiselimod

关于Amiselimod

Amiselimod is a sphingosine-1-phosphate (S1P) receptor functional antagonist and, by inhibiting the receptor function of the lymphocyte sphingosine-1-phosphate (S1P) receptor, retains lymphocytes sequestered in the lymph nodes and prevents them from contributing to autoimmune reactions.1 Due to this mechanism of action, Amiselimod may potentially be useful for various autoimmune diseases.2 Affinity to S1P1 and S1P5 receptor subtypes, suggests that Amiselimod could potentially have a more pronounced effect on ulcerative colitis related inflammation than compounds with restricted activity on S1P1 receptor subtype exclusively or combined activity on S1P1 and S1P5.

阿米塞利莫是一种鞘氨醇-1-磷酸（S1P）受体功能拮抗剂，通过抑制淋巴细胞鞘氨醇-1-磷酸（S1P）受体的受体功能，保留了淋巴结中隔离的淋巴细胞，防止它们参与自身免疫反应。由于这种作用机制，阿米塞利莫可能对各种自身免疫性疾病有用。2对S1P1和S1P5受体亚型的亲和力表明，阿米塞利莫可能对溃疡性结肠炎相关炎症的影响比仅对S1P1受体亚型具有限制活性或对S1P1和S1P5具有联合活性的化合物更为显着。

3.

3.

About Salix

关于Salix

Salix Pharmaceuticals is one of the largest specialty pharmaceutical companies in the world committed to the prevention and treatment of gastrointestinal diseases. For more than 30 years, Salix has licensed, developed, and marketed innovative products to improve patients' lives and provide health care providers with life-changing solutions for many chronic and debilitating conditions.

Salix Pharmaceuticals是世界上最大的专业制药公司之一，致力于预防和治疗胃肠道疾病。30多年来，Salix一直在许可、开发和销售创新产品，以改善患者的生活，并为医疗保健提供者提供许多慢性病和衰弱性疾病的改变生活的解决方案。

Salix currently markets its product line to U.S. health care providers through an expanded sales force that focuses on gastroenterology, hepatology, pain specialists, and primary care. Salix is headquartered in Bridgewater, New Jersey. For more information about Salix, visit www.Salix.com and connect with us on Twitter and LinkedIn..

Salix目前通过扩大销售队伍向美国医疗保健提供者销售其产品线，该销售队伍专注于胃肠病、肝病、疼痛专家和初级保健。Salix总部位于新泽西州布里奇沃特。有关Salix的更多信息，请访问www.Salix.com，并通过Twitter和LinkedIn与我们联系。。

About Bausch Health

关于Bausch Health

Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) is a global diversified pharmaceutical company enriching lives through our relentless drive to deliver better health outcomes. We develop, manufacture and market a range of products, primarily in gastroenterology, hepatology, neurology, dermatology, medical aesthetic devices, international pharmaceuticals, and eye health, through our controlling interest in Bausch + Lomb.

Bausch Health Companys Inc.（纽约证券交易所代码：BHC）（多伦多证券交易所代码：BHC）是一家全球多元化的制药公司，通过我们不懈的努力提供更好的健康结果，丰富了人们的生活。我们通过对博士伦的控股，开发、制造和销售一系列产品，主要涉及肠胃病学、肝病学、神经病学、皮肤病学、医疗美容器械、国际制药和眼部健康。

Our ambition is to be a globally integrated healthcare company, trusted and valued by patients, HCPs, employees and investors. For more information, visit www.bauschhealth.com and connect with us on Twitter and LinkedIn..

我们的目标是成为一家全球一体化的医疗保健公司，受到患者、医务人员、员工和投资者的信任和重视。有关更多信息，请访问www.bauschhealth.com，并通过Twitter和LinkedIn与我们联系。。

About DDW

关于DDW

Digestive Disease Week® (DDW) is the largest international gathering of physicians, researchers and academics in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery. Jointly sponsored by the American Association for the Study of Liver Diseases (AASLD), the American Gastroenterological Association (AGA), the American Society for Gastrointestinal Endoscopy (ASGE) and the Society for Surgery of the Alimentary Tract (SSAT), DDW is an in-person and online meeting from May 18-21, 2024.

消化疾病周（DDW）是消化内科、肝病学、内窥镜检查和胃肠外科领域最大的国际医师、研究人员和学者聚会。DDW由美国肝病研究协会（AASLD）、美国胃肠病学会（AGA）、美国胃肠内镜学会（ASGE）和消化道外科学会（SSAT）联合赞助，于2024年5月18日至21日举行面对面的在线会议。

The meeting showcases more than 4,400 abstracts and hundreds of lectures on the latest advances in GI research, medicine and technology. More information can be found at www.ddw.org..

会议展示了4400多篇摘要和数百篇关于胃肠道研究、医学和技术最新进展的讲座。有关更多信息，请访问www.ddw.org。。

References

参考文献

1. Kunio Sugahara, Yasuhiro Maeda. Amiselimod, a novel sphingosine 1‐phosphate receptor‐1 modulator, has potent therapeutic efficacy for autoimmune diseases, with low bradycardia risk. British Journal of Pharmacology. January 2017.

1、杉原久夫、前田康弘。Amiselimod是一种新型鞘氨醇1-磷酸受体-1调节剂，对自身免疫性疾病具有有效的治疗效果，心动过缓风险低。英国药理学杂志。2017年1月。

2. Peyrin-Biroulet, Ronald Christopher Modulation of sphingosine-1-phosphate in inflammatory bowel disease. Autoimmunity Reviews. February 2017.

2.Peyrin Biroulet，Ronald Christopher在炎症性肠病中调节鞘氨醇-1-磷酸。自身免疫评论。2017年2月。

3. BiseraStepanovska, AndreaHuwiler. Targeting the S1P receptor signaling pathways as a promising approach for treatment of autoimmune and inflammatory diseases. Pharmacological Research. February 2019.

3.BiseraStepanovska，AndreaHuwiler。靶向S1P受体信号传导途径作为治疗自身免疫性和炎性疾病的有前途的方法。药理学研究。2019年2月。

Investor Contact:

投资者联系人：

Media Contact:

媒体联系人：

Garen Sarafian

Garen Sarafian

Kevin Wiggins

凯文·威金斯

ir@bauschhealth.com

ir@bauschhealth.com

corporate.communications@bauschhealth.com

corporate.communications@bauschhealth.com

(877) 281-6642 (toll-free)

（877）281-6642（免费电话）

(908) 541-3785

(908) 541-3785

SOURCE: Salix Pharmaceuticals

来源：Salix Pharmaceuticals

View the original press release on accesswire.com

在accesswire.com上查看原始新闻稿